October 22, 2020
Business News

Moderna Stock Soars on Promising Coronavirus Vaccine Trial News – Motley Fool

Shares of Moderna’s (NASDAQ:MRNA) leapt 7% on Wednesday, furthering the biotech’s torrid gains — of more than 315% — so far in 2020. 
On Tuesday, a peer-reviewed interim analysis of Moderna’s phase 1 study of its COVID-19 vaccine, mRNA-1273, was published in The New England Journal of Medicine. The results showed that neutralizing antibodies — which researchers are hopeful will help to prevent infection by the novel coronavirus that causes COVID-19 — were found in 100% of evaluated particip…

Click here to view the original article.

Related Posts

You might also like ...

RETA Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Reata Pharmaceuticals, Inc. Shareholders of Class Action and Encourages Shareholders to Contact the Firm
dentsu International Taps Keith Lippiatt as Global Chief Operating Officer for its CXM Line of Business
Colorado Can Save Money, Create Jobs and Reduce Greenhouse Gas Emissions by Enabling Transmission Coordination Across the State